Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases

NCT ID: NCT01191632

Last Updated: 2010-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The efficiency of T cell based immunotherapies is affected by the insufficient migration and activity of tumor specific effector T cells in the tumor. Aim of this phase I/II clinical trial is to evaluate whether a neoadjuvant, low dose radiotherapy can improve T cell connected anti tumor immune response in colorectal liver metastases.

The primary endpoint is the number of tumor infiltrating T cells. Furthermore the T cell activity in situ, the number of regulatory T cells and the frequency of tumor reactive T cells in the blood and bone marrow will be examined.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Liver Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiation 0,5Gy

Radiation: one time Radiation with an intensity of 0.5 Gy Group A

Beginning on a weekday 48 hours before surgery

Group Type ACTIVE_COMPARATOR

one time radiation

Intervention Type RADIATION

Radiation: one time Radiation with an intensity of

0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery

No radiation

Control group with 0Gy radiation

Group Type ACTIVE_COMPARATOR

No Radiation

Intervention Type RADIATION

Control group with 0Gy

Radiation 2Gy

Radiation: one time Radiation with an intensity of

2.0 Gy Group B

Beginning on a weekday 48 hours before surgery

Group Type ACTIVE_COMPARATOR

one time radiation

Intervention Type RADIATION

Radiation: one time Radiation with an intensity of

0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery

Radiation 5Gy

Radiation: one time Radiation with an intensity of

5 Gy Group C Beginning on a weekday 48 hours before surgery

Group Type ACTIVE_COMPARATOR

one time radiation

Intervention Type RADIATION

Radiation: one time Radiation with an intensity of

0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

one time radiation

Radiation: one time Radiation with an intensity of

0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery

Intervention Type RADIATION

No Radiation

Control group with 0Gy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability of subject to understand character and individual consequences of the clinical trial
* Written informed consent (must be available before enrolment in the trial)
* Age ≥ 50 years
* Radiological urgently suspected colorectal liver metastasis

Exclusion Criteria

* second malignancy
* Pregnancy and lactation
* no prior liver radiation
* liver metastasis must be resectable
Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heidelberg University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of surgery, university of Heidelberg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Heidelberg

Heidelberg, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juergen Weitz, MD

Role: CONTACT

+49 6221 56 6250

Christoph Reissfelder, MD

Role: CONTACT

+49 6221 56 6250

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juergen Weitz

Role: primary

+49 6221 56 6250

Christoph Reissfelder

Role: backup

+49 6221 56 6250

References

Explore related publications, articles, or registry entries linked to this study.

Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Buchler MW, Beckhove P, Huber PE, Weitz J. A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer. 2011 Sep 30;11:419. doi: 10.1186/1471-2407-11-419.

Reference Type DERIVED
PMID: 21961577 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S081/2008

Identifier Type: -

Identifier Source: org_study_id